Drug Database
BO

botulism+tetanus vaccine

✓ Approved

Microgen · Vaccine · Vaccine

What is botulism+tetanus vaccine?

botulism+tetanus vaccine is a vaccine developed by Microgen. It is approved for therapeutic indications via injectable (others) or subcutaneous injection.

Drug Profile

CompanyMicrogen
Drug ClassVaccine
RouteInjectable (Others), Subcutaneous Injection
StatusApproved

Therapeutic Indications

botulism+tetanus vaccine is developed for 2 unique indications across 1 therapeutic area.

Therapeutic AreaConditionPhase
Infections and infestationsBotulism✓ Approved
Infections and infestationsTetanus✓ Approved

Related Research Articles

PubMedCureus2026-07-17

Generalized Tetanus in an Unvaccinated 52-Year-Old Male Gardener: Diagnostic and Therapeutic Challenges in a Low-Resource Setting.

Qadri Imman I, AlKhawaja Raneem E RE, Mathew Rahul S RS, Khan Israr A IA et al.

Tetanus remains a life-threatening but preventable disease, which continues to manifest in adults lacking sufficient tetanus vaccination and accessibility to tetanus immunoglobulin (TIG). The case discussed is of an unvaccinated 52-year-old Pakistani male patient who developed progressive trismus, difficulty in swallowing, and general spasms following a minor foot wound. The early symptomatology was attributed to psychological stress or heat exhaustion; thus, there was an initial delay in diagnosis. His clinical course was further complicated by the unavailability of TIG, severe autonomic dysfunction, and respiratory compromise requiring prolonged mechanical ventilation and intensive care support. This case is consistent with global patterns, in which unvaccinated adult males with neglected wounds are disproportionately affected, while delayed diagnosis and limited access to immunoglobulin contribute to poorer outcomes. Although intensive care management may help control complications, prolonged recovery with persistent functional impairment is common in the absence of definitive toxin neutralization. This case underscores the need for strengthened tetanus booster vaccination programs, increased clinical awareness of atypical presentations, and resource-sensitive healthcare policies to ensure timely availability of TIG in emergency settings.

PubMedBMJ public health2026-07-17

Prevalence of zero-dose vaccination and its associated factors in urban areas of Somali region, Ethiopia: a mixed-methods approach.

Elmi Abdifatah A, Ibrahim Mahamed M, Farah Abdi A, Tahir Ahmed A et al.

Despite global progress in immunisation, vaccine coverage remains uneven in many low- and middle-income countries. Urbanisation has widened disparities, particularly among children in informal settlements. Ethiopia has a high zero-dose burden, with the Somali region identified as a hotspot. However, urban areas in this region remain understudied. This study assesses the prevalence of zero-dose children and associated factors in urban areas of the Somali region to inform targeted interventions. Using a mixed-methods approach, data were collected from 842 households in three urban towns through community surveys and six key informant interviews. The primary outcome was the proportion of zero-dose children, defined as those who had not received the first dose of the DTP-containing vaccine (Penta-1) during their first year of life, based on vaccination card records or caregiver recall. This included children who had never received any vaccine or had received some vaccines but not Penta-1. Quantitative data were analysed using logistic regression, while qualitative findings were examined thematically using the GAVI IRMMA framework. Strict quality control measures ensured the reliability of results. Of 842 targeted households, 827 participated (98.2% response). Findings reveal that 30% of children surveyed were identified as zero-dose for vaccination. Children were significantly more likely to be zero-dose if their mothers had no antenatal care (adjusted OR, AOR ~5.0), required permission for vaccination (AOR ~3.4), delivered at home (AOR ~3.1), or did not receive the second dose of tetanus toxoid (AOR ~2.7). In contrast, higher perceived household wealth and at least one postnatal care visit reduced the likelihood of zero-dose by about 45% and 55%, respectively. Zero-dose children were concentrated in urban peripheries and informal settlements with limited healthcare access, poor identification strategies and reliance on facility-based vaccination services. The study highlights a higher prevalence of zero-dose children in urban areas, underscoring the urgent need for improved identification and mapping in underserved communities. Strengthening advocacy, diversifying immunisation approaches and addressing systemic barriers are essential to improving vaccine access and reducing the zero-dose burden.

PubMedClinical infectious diseases : an official publication of the Infectious Diseases Society of America2026-07-17

Artificial Intelligence Across the Vaccine Clinical Trial Lifecycle: Evidence, Readiness, and Guardrails.

Idriss Jad J, Kalash Suha S, Faraj Jana Abu JA, Nolan Lauren L et al.

Artificial intelligence (AI) is increasingly being used to support clinical research, but its value in vaccine clinical trials requires careful evidence-based assessment. Vaccine trials pose distinctive challenges, including high safety expectations in healthy participants, evolving pathogen exposure and baseline immunity, incomplete correlates of protection, applicability of findings to intended-use populations, and intense public scrutiny. We conducted a structured, vaccine-focused narrative review of AI applications across the vaccine trial lifecycle, supplemented by targeted clinical trial and vaccine pharmacovigilance studies with directly transferable methods. In the combined evidence base, evidence is strongest for operational uses, particularly recruitment, eligibility screening, trial matching, and risk-based monitoring. Applications to immune-response interpretation, correlates of protection, and vaccine safety surveillance are promising but remain less prospectively validated. Responsible adoption should be guided by intended tool use, evidence of strength, data governance, regulatory expectations, and preservation of human scientific and safety judgment.

PubMedIranian journal of nursing and midwifery research2026-07-17

Investigate the Relationship Between Receiving the COVID-19 Vaccine and Menstrual Disorders among Females of Reproductive Age in Jeddah, Saudi Arabia.

Esheaba Ola M OM, Fouly Howieda A HA, Kassem Fathia K FK

There are many physical side effects of the COVID-19 vaccine, including unexpected changes occurring in menstrual bleeding. This study aimed to assess the relation between the COVID-19 vaccine and disorders in menstruation among females of reproductive age. Participants were recruited from a nonprobability snowball sampling targeted at females who are living in Jeddah city between March 2022 and August 2022, Kingdom of Saudi Arabia (KSA). A quantitative cross-sectional design was utilized to conduct the study, a nonexperimental design based on a single observation point. The sample size is estimated by the G*Power software to be 180, considering missed cases, it increased to 197. Regarding menstrual changes, n = 86 (43.65%) experienced a delay, and about one-third reported an earlier menstruation cycle. A significant relationship is observed between nationality, occupation, and changes in period (t = 3.89, P < 0.001 and t = -2.94, P < 0.004). There is no significant difference in the occurrence of complications among the different vaccine types. Receiving the COVID-19 vaccine was strongly linked with unexpected disturbance in menstruation among the studied group, from simple menstrual irregulates to reported amenorrhea after receiving the booster doses. However, the occurrence of menstrual cycle delays was not linked to the vaccine type. Further studies should be done to investigate each type of vaccine specifically to determine if the type of vaccine affects the reproductive function generally not only the menstrual cycle, in a larger survey for more generalizability.

PubMedFrontiers in public health2026-07-17

Reframing vaccine narrative: a co-production study of a media campaign intervention to address childhood vaccine hesitancy among Nigerian parents and caregivers.

Ike Tarela Juliet TJ, Jidong Dung Ezekiel DE, Obi Callistar Kidochukwu CK, Ntaji Maureen Iru MI et al.

Childhood vaccine hesitancy is a public health concern. Nigeria is one of the countries with the highest rates of zero-dose childhood vaccination. This study makes an original contribution by adopting a co-production approach underpinned by interpretative phenomenological analysis (IPA) to meaningfully inform the co-production of a media campaign intervention with Nigerian parents/ caregivers whose child(ren) are not, or only partially, up to date with routine immunizations aimed at reducing childhood vaccine hesitancy and promoting uptake. A total of 10 parents or caregivers whose children were not up to date with their vaccinations were recruited for the study and participated in a focus group discussion. Data were analyzed using IPA. The findings reveal that hostility, misinformation, and the breakdown of trust in vaccines, alongside faith, tradition, and the lived logic of alternative protection, intersect to exacerbate hesitancy. The findings also reveal that clarity, reassurance, and empowerment in vaccine communication, underpinned by gendered voices, can build trust in vaccine messaging and encourage uptake. The study offers important insights for policymakers and public health communication strategies, underscoring the need for culturally appropriate media campaign interventions that address vaccine-related concerns and foster uptake.

PubMedVaccine2026-07-17

Protective immunity of lectin-adjuvanted intraperitoneal injection vaccine against Aeromonas veronii infection in Oreochromis niloticus.

Guha Ritam R, Wangkahart Eakapol E, Elumalai Preetham P

Disease outbreaks caused by Aeromonas veronii pose a significant threat to Nile tilapia (Oreochromis niloticus) aquaculture. Lectin-based adjuvants, such as concanavalin A (ConA), can potentially enhance vaccine efficacy by stimulating both innate and adaptive immunity. This study evaluated the immunoprotective potential of a ConA-adjuvanted, formalin-inactivated A. veronii vaccine administered intraperitoneally. Nile tilapia were vaccinated intraperitoneally with the inactivated A. veronii vaccine formulated with ConA. Safety was assessed by monitoring fish behavior and physiological responses. Innate immune activation was evaluated through lysozyme (LZM), myeloperoxidase (MPO), and superoxide dismutase (SOD) assays. Humoral response was measured via serum IgM levels. Gene expression in head kidney and spleen tissues was analyzed for TCR-β, IgM, MHC -II, CD4, and proinflammatory cytokines (IL-1β, IL-8). Protective efficacy was determined by challenging vaccinated fish with live A. veronii and calculating relative percent survival (RPS). The vaccine was safe, with no adverse effects observed. Vaccinated fish showed significant increases in LZM, MPO, and SOD activities, indicating enhanced innate immunity. Serum IgM levels peaked at 42 days post-vaccination, demonstrating robust humoral response. Gene expression analysis revealed upregulation of immune markers confirming activation of humoral (IgM), proinflammatory cytokine (IL-1β, IL-8) and cell-mediated pathways (TCR-β, MHC-II, CD4). Following challenge, the ConA-adjuvanted vaccine group exhibited the highest RPS (79%), significantly higher than controls. These results highlight the potent immunostimulatory effect of ConA and the vaccine's capacity to bridge innate and adaptive immunity in Nile tilapia. The adjuvant effects of ConA have improved the vaccine efficacy and immunogenicity.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about botulism+tetanus vaccine